Explore SR-9009 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
SR-9009 (stenabolic) is a REV-ERB agonist — a small molecule, not a peptide or SARM — sourced in research for endurance and metabolic studies. It ships as capsules or a powder; note the published pharmacology reports very poor oral absorption.
REV-ERBα is a heme-binding nuclear receptor that acts as a constitutive transcriptional repressor of clock genes and metabolic-program genes. SR-9009 binds REV-ERB and enhances its transcriptional-repressor activity, driving a metabolic-program shift in skeletal muscle and liver that pre-clinically increases fatty-acid oxidation, improves mitochondrial function, and produces an "exercise-mimetic" phenotype in mice.[4][5] **The orally-administered SR-9009 was used in the Burris lab's in-vivo mouse work primarily by intraperitoneal injection, not oral; the oral bioavailability is reported as very low and the in-vivo human relevance of any oral consumer dose is uncertain.[1][2]**
The founding Solt et al. (Nature 2012) paper characterised SR-9009 as a REV-ERB agonist with metabolic-program effects in mice.[1] Woldt et al. (Nat Med 2013) extended the work to skeletal-muscle mitochondrial function and exercise capacity in mice.[5] Both used parenteral (intraperitoneal) administration in the in-vivo experiments. No human trial has been registered or published.[6] The "stenabolic" consumer market exists entirely outside any human pharmacokinetic, pharmacodynamic, or safety study.
Not FDA-approved. No registered clinical trial. Pre-clinical only, primarily by parenteral administration in mice. Poor oral bioavailability published in the original pharmacology paper. WADA-prohibited at all times under S4.5. Research-grade material only.
SR-9009 has a reported half-life of ~4 hours (pre-clinical). The pharmacokinetic reference models an interval of multiple times daily; this is not a measured community cadence or a dosing recommendation. A short half-life and poor oral bioavailability are why stenabolic is dosed several times a day; levels fall off quickly between doses. Data come from rodent studies. Pharmacokinetic source: Pre-clinical (mouse) data (Solt et al. Nature 2012); not characterised in humans. It is catalogued under Other Peptides on WPA.
The WPA community has not yet logged enough SR-9009 calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.